Loading...
•
Jun 30
AptarGroup Q2 2025 Earnings Report
AptarGroup's second quarter 2025 results were reported, showing increases in sales, net income, and earnings per share compared to the prior year quarter.
Key Takeaways
AptarGroup delivered a solid second quarter in 2025, with reported sales increasing by 6% and core sales by 3%. Net income rose by 24% to $112 million, and reported EPS increased by 25% to $1.67. All segments contributed positively, with Pharma and Closures driving growth through increased volumes and higher-value products. The company also returned $100 million to shareholders through share repurchases and dividends.
Reported sales increased 6% to $966 million, with core sales up 3% compared to the prior year quarter.
Net income grew 24% to $112 million, and reported earnings per share increased 25% to $1.67.
Adjusted EBITDA increased 13% to $218 million, achieving an adjusted EBITDA margin of 22.6%, a 140 basis point increase.
Aptar returned $100 million to shareholders through share repurchases and dividends during the quarter.
AptarGroup
AptarGroup
AptarGroup Revenue by Segment
Revenue by Segment
Aptar Pharma Revenue
CapyFin.comAptar Beauty Revenue
CapyFin.comAptar Closures Revenue
CapyFin.com Forward Guidance
Aptar expects a solid third quarter in 2025, with continued strength in Pharma, particularly Injectables, driven by rising demand for higher-value elastomeric components. They anticipate modest contributions from Closures and Beauty segments and remain focused on cost discipline.
Positive Outlook
- Continued strength in Pharma, especially Injectables, due to rising demand for higher-value elastomeric components.
- Growth in Injectables fueled by biologics, GLP-1 therapies, and Annex 1 compliance requirements.
- Anticipated modest contributions from Closures segment.
- Anticipated modest contributions from Beauty segment.
- Ongoing focus on cost discipline across all segments.
Challenges Ahead
- Naloxone sales are expected to normalize after a period of rapid growth, posing a challenge.
- Elevated levels of cough and cold inventory in Europe are expected to persist through the quarter.
- Higher legal fees of approximately 6 to 7 cents per share associated with litigating pharma intellectual property rights.
- The pace of new fragrance launches remained subdued due to tariff-related uncertainties in the prior quarter, which may continue to impact Beauty.
- Lower demand in beauty dispensing technologies for fragrance and full pack solutions in the prior quarter, which may persist.